Publication date: Sep 05, 2019
How to stop MS in its tracks – Science Weekly podcast Ian Sample visitsProfessor Richard Reynolds at theMS Society tissue bank to hear how research on brains of patients who died withmultiple sclerosis is leading to novel insights and new treatmentsContinue reading. .. Source: – Category: Science Authors: Presented by Ian Sample and produced by Max Sanderson and Iain Chambers Tags: Science Multiple sclerosis Society Neuroscience Parkinson’s disease Health Medicine Source Type: news Authors: Xiong H, Tuo QZ, Guo YJ, Lei P Abstract Iron has been proposed to be responsible for neuronal loss in several diseases of the central nervous system, including Alzheimer’s disease (AD), Parkinson’s disease (PD), stroke, Friedreich’s ataxia (FRDA), multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS). The most common etiologies include acute changes due to (1) delirium or stroke, (2) movement disorders (Alzheimer dementia, Parkinson disease, multiple sclerosis, epilepsy), and (3) mood/behavior disorders (major depressive disorder, anxiety, bipolar disorder, schizophrenia). Among neurological diseases, epilepsy, dementia, Parkinson disea. .. Abstract Neurodegenerative diseases are progressive and uncontrolled gradual loss of motor neurons function or death of neuron cells in the central nervous system (CNS) and the mechanisms underlying their progressive nature remain elusive. There is urgent need to investigate therapeutic strategies and novel treatments for neural regeneration in disorders like Alzheimer’s disease (AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS). Lloyd had forgotten the name of her grandma’s disease, hadn’t thought about it in .. . Purpose of review To review recent studies which assess comorbidity, that is, prevalence of co-occurrence, relationships and treatment implications between anxiety disorders and various medical illnesses. Recent findings The prevalence rates of anxiety disorders in patients with medical illnesses are high, with percentage up to 29% in patients with epilepsy, 48. 9% in patients with multiple sclerosis, 30. 1% in patients with Parkinson’s disease, 30% in patients with cardiovascular disease, 47. 0% in patients with diabetes mellitus, and so on. Abstract Chronic neurodegenerative and neuroinflammatory diseases, such as idiopathic Parkinson’s syndrome, amyotrophic lateral sclerosis and multiple sclerosis, represent a therapeutic challenge.